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Abstract 
Bone tissue is a dynamic structure, constantly being remodeled to repair small injuries 
and maintain homeostasis. The regenerative capacity of bone may be impaired by clinical 
conditions such as bone disorders, and large or complex defects or fractures, which are 
particularly relevant in ageing populations. Research on the development of new biomaterials 
for bone repair tends to focus on osteoblasts, the bone forming cells, their metabolism and 
behavior towards other cells, drugs and implanted materials. On the other hand, osteoclasts, the 
bone resorbing cells, are much less explored, despite their interactions with other cells, 
including osteoblasts, and their remodeling activity playing crucial roles in bone repair and 
regeneration. As such, understanding osteoclast behavior must be one of the key factors to have 
into account when designing novel biomaterials for bone regeneration. Biological polymers, 
such as those made of proteins, have shown great potential in tissue repair and regeneration, 
thus the research interest in this kind of biomaterials is increasing. Fibrinogen is classically 
defined as a pro-inflammantory protein with pro-healing properties, and previous results have 
shown that it can be used in biomaterials, to promote bone regeneration. 
The main aims of this work were to assess the differentiation of mature and functional 
osteoclasts in fibrinogen scaffolds (Fg-3D), and compare it to macrophages. Also, to evaluate 
their capacity to degrade Fg-3D and the effect of their paracrine factors on mesenchymal stem 
cells (MSC) osteogenic differentiation. 
Fg-3D scaffolds were prepared by freeze-drying and characterized by scanning electron 
microscopy. Monocyte-derived macrophages were differentiated without addition of cytokines, 
while osteoclasts were differentiated in presence of RANKL and M-CSF. Cytotoxicity of Fg-3D 
extracts was inferred from cell morphology and survival, before cells were cultured directly on 
the scaffolds. Osteoclast differentiation in Fg-3D was evaluated by cell morphology and 
expression of enzymes cathepsin K and tartrate resistant acid phosphatase (TRAP). Conditioned 
media was collected along the cultures. Scaffold degradation was assessed through area 
measurement and D-dimer quantification. MSC were cultured on Fg-3D in presence of 
osteoclast or macrophage conditioned media, and osteogenic differentiation was assessed by 
alkaline phosphatase (ALP) production. TGF-1 was also quantified in conditioned media by 
ELISA. 
Fg-3D extracts were found to be cytotoxic to primary macrophages and osteoclasts, 
while adsorbed fibrinogen was not. When cultured directly in Fg-3D cathepsin K and TRAP-
positive multinucleated osteoclasts were formed. Macrophages remained largely mononucleated 
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and expressed only TRAP. Although osteoclasts and macrophages were both capable of 
degrading Fg-3D over culture time, osteoclasts appeared more efficient. Remarkably, 
conditioned media from osteoclasts and macrophages at early differentiation stages promoted 
MSC osteogenic differentiation, to levels similar to the positive control. The levels of TGF-1 
were also higher on the first week of differentiation, decreasing afterwards. 
Taken together, our results suggest that both osteoclasts and macrophages are able to 
differentiate and are active in Fg-3D, having a positive influence on MSC osteogenic 
differentiation, potentially promoted by TGF-1. 
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Resumo 
O tecido ósseo tem uma estrutura dinâmica, sendo constantemente remodelado para 
reparar pequenas lesões e manter a homeostasia. Indivíduos saudáveis conseguem regenerar 
rapidamente pequenas lesões ósseas, mas doenças ósseas, assim como lesões maiores e/ou mais 
complexas, constituem problemas de saúde que se agravam em populações envelhecidas. A 
investigação sobre o desenvolvimento de novos biomateriais para reparação do osso tende a 
concentrar-se nos osteoblastos, as células formadoras de osso, o seu metabolismo e 
comportamento em relação a outras células, medicamentos e biomateriais. Por outro lado, os 
osteoclastos, células de reabsorção do osso, são muito menos explorados. No entanto, as suas 
interações com outras células, incluindo os osteoblastos, e a sua atividade de reabsorção 
desempenham um papel crucial em processos de reparação e regeneração óssea. Assim sendo, 
um melhor conhecimento do comportamento dos osteoclastos deve um dos principais fatores a 
ter em conta na concepção de novos biomateriais para regeneração óssea. Os polímeros 
biológicos, como os constituídos por proteínas, têm revelado grande potencial na reparação e 
regeneração dos tecidos, despertando assim o interesse crescente nestes materiais. O 
fibrinogénio é uma proteína pró-inflamatória, com um papel relevante na cicatrização e 
regeneração de tecidos. Trabalhos anteriores demonstram que o fibrinogénio pode ser usado em 
biomateriais, para promover a regeneração óssea. 
Os principais objetivos deste trabalho foram a avaliação da diferenciação de 
osteoclastos funcionais em estruturas porosas de fibrinogénio (Fg-3D), em comparação com 
macrófagos, assim como a avaliação da sua capacidade para degradar as Fg-3D e do efeito de 
fatores parácrinos, secretados pelos osteoclastos, na diferenciação osteogénica de células 
estaminais mesenquimais (MSC). 
As Fg-3D foram produzidas por liofilização e caracterizadas por microscopia eletrónica 
de varrimento. Macrófagos derivados de monócitos foram diferenciados sem a adição de 
citocinas, enquanto que os osteoclastos foram induzidos a diferenciar na presença de RANKL e 
M-CSF. A citotoxicidade de extratos de Fg-3D foi inferida a partir da morfologia celular e sua 
viabilidade, antes das células serem cultivadas diretamente em Fg-3D. A diferenciação dos 
osteoclatos cultivados em Fg-3D foi avaliada pela morfologia celular e pela expressão das 
enzimas catepsina K e fosfatase ácida resistente ao tartrato (TRAP). O meio condicionado foi 
recolhido ao longo da cultura. A degradação da estrutura de fibrinogénio foi determinada pela 
medição da área e quantificação de D-dímero. As MSC foram cultivadas em Fg-3D na presença 
de meios condicionados de osteoclastos e macrófagos e a sua diferenciação osteogénica foi 
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avaliada pela produção de fosfatase alcalina (ALP). A quantidade de TGF-β1 nos meios 
condicionados foi determinada por ELISA. 
Os extratos de Fg-3D foram citotóxicos para os osteoclastos e macrófagos primários, 
mas o fibrinogénio adsorvido não o foi. Quando cultivados diretamente em Fg-3D, formaram-se 
osteoclastos multinucleados e que expressavam catepsina K e TRAP. Os osteoclastos e os 
macrófagos foram capazes de degradar Fg-3D ao longo do tempo de cultura, mas os 
osteoclastos foram mais eficientes. Além disso, os meios condicionados de osteoclastos e 
macrófagos em fases de diferenciação precoces promoveram a diferenciação osteogênica das 
MSC em níveis semelhantes aos observados para o controlo positivo. Os níveis de TGF-1 
também foram mais elevados na primeira semana de diferenciação, diminuindo ao longo do 
tempo de cultura. 
Os resultados apresentados sugerem que tanto os osteoclastos como os macrófagos são 
capazes de se diferenciar e manter-se ativos quando cultivados em Fg-3D, tendo uma influência 
positiva na diferenciação osteogénica das MSC, provavelmente promovida por TGF-1. 
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1. Introduction 
 
1.1. The bone system 
The bone system is formed essentially by bone and cartilage tissues, which come 
together in articulated joints that allow freedom of movement. Bone tissue is formed by cells 
and extracellular matrix (ECM) which includes an organic component, composed of collagen 
type I (up to 95% of bone organic composition), non-collagenous proteins (such as osteocalcin, 
osteopontin, osteonectin and bone sialoprotein) and proteoglycans (such as biglycan and 
decorin), and an inorganic component, mainly of hydroxyapatite crystals, formed from calcium 
and phosphorus, and placed into the organic matrix. The combination of these two components 
grants bone its characteristic rigidity and strength, while maintaining an appropriate degree of 
elasticity [1]. 
The main function of the bone system is to provide support to the body, as the skeleton 
forms a rigid structure to which softer tissues are attached, while also contributing for the 
movement of the body by working as a lever when muscles contract. Additionally, the bone 
system plays important roles in protecting vital organs, like the brain or the heart and lungs, 
protected by the skull and the ribcage, respectively; storage of minerals such as calcium and 
phosphate in hydroxyapatite crystals or magnesium and sodium; growth factors storage, for 
example bone morphogenic proteins; and hematopoiesis or blood cell formation (white and red 
cells, and platelets) in the bone marrow [1, 2]. 
The Harversian System, also known as osteon, is the structural unit of bone. Osteons 
resemble an elongated cylinder parallel to the bone axis and are composed of heavily packed 
collagen fibrils, called the lamellae. Lamellae’s function is to withstand torsion stresses, hence 
its fibrils orientation [2]. 
Bone tissue can have different structures, properties and functions. Cortical bone, also 
known as compact bone, constitutes an exterior layer, has dense bone matrix with passageways 
for blood, lymphatic vessels and nerves. Its main functions are mechanical support and 
protection of trabecular bone and organs. Unlike compact bone, cancellous or trabecular bone, 
also known as spongy bone, has a loosely organized matrix, with pores and trabeculae. The 
trabecular bone is where the bone metabolic functions are carried out. Some long bones (e.g. 
femur) have an additional compartment, the medullary cavity, filled with bone marrow [2]. 
Despite its appearance, bone is not a static tissue and is continually suffering alterations 
by remodeling, name given to the process of replacing old bone for new bone, in order to adapt 
to new stimuli from the environment, such as mechanical loads or necessity of mineral 
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homeostasis [3]. The remodeling process is performed by the bone cells: osteoblasts, 
responsible for bone formation, and osteoclasts, involved in bone resorption [2]. The 
deregulation of the remodeling process gives origin to several bone related diseases [3]. 
In the next sub-sections the biology of bone cells and their role in the process of bone 
remodeling are addressed, paving the way to review bone diseases and therapies, including the 
use of biomaterials for bone tissue repair and regeneration.  
 
1.2. Osteoblasts and bone formation 
Osteoblasts and osteoclast, the bone cells involved in remodeling, derive from distinct 
lineages, and have different life cycles and functions. 
Osteoblasts are derived from mesenchymal stem cells (MSC) which have the potential 
to differentiate in the different cells of the mesodermal tissues, like osteoblasts, adipocytes, 
stromal cells, myoblasts, tenocytes and chondrocytes [1, 4]. MSC undergo several chances in 
metabolism and phenotype during osteoblastic differentiation. This process can be divided in 
three phases, with cells going through different stages of differentiation. In particular, MSC 
differentiate into osteoprogenitor cells, then into pre-osteoblasts and finally into mature 
osteoblasts [5]. Their differentiation is regulated by several molecular factors, including: bone 
morphogenetic proteins (BMPs),  platelet derived growth factor (PDGF), fibroblast growth 
factor (FGF), insulin-like growth factors (IGFs), transforming growth factor β (TGF-β), 
interleukin 1β (IL-1β), interleukin 5  (IL-5) and tumor necrosis factor α (TNF-α) [5-7]. The Wnt 
signaling pathways have been reported to be involved in regulating gene transcription in 
osteoblast progenitor cells, and specially MSC, by stabilization of β-catenin [8]. 
The most explored mediators of osteoblast differentiation are BPMs, in particular BMP-
2, BMP-4 and BMP-7, which up-regulate the transcription factors Cfba/Run-2. These BMPs are 
up-regulated through the activation of the Shh and Wnt signaling pathways and act on MSC, 
osteoprogenitor cells and pre-osteoblasts [5]. PDGF and TGF-β are reported to have an 
important role at early stages, recruiting MSC to the site of differentiation and/or stimulating 
proliferation of the osteoblast progenitors [5, 9]. Nonetheless, TGF-β has also been reported to 
inhibit later differentiation and mineral deposition by mature osteoblasts [5]. Later in the 
differentiation process IGFs up-regulate the transcription factor osterix, leading to late stage 
differentiation [5], and FGF reinforces the differentiation of already committed cells into the 
osteoblastic lineage, and also has a role in osteoblast apoptosis [7].  
Mature osteoblasts express several transcriptions factors like Runx-2, osterix, Msx-2, 
Dlx-5 and the AP-family [5, 10], and several phenotypic markers that are important for bone 
formation [11], such as bone matrix proteins, like collagen type I, osteocalcin, osteopontin and 
bone sialoprotein. The ALP enzyme present at the osteoblast cell membrane and involved in 
bone mineralization, is greatly unregulated during bone formation phases, and usually 
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constitutes a hallmark of osteoblastic differentiation [12]. Parathyroid hormone/parathyroid 
hormone receptors (PTH/PTHr) that regulate calcium and phosphate ions homeostasis [1, 5], are 
also a osteoblastic products. 
The average lifespan of an osteoblast is around one month, after it either undergoes 
apoptosis, being replaced in its role by new functional osteoblasts, or it is embedded in the bone 
matrix as an osteocyte, which is considered the last phase of osteogenic differentiation [5]. 
Osteocytes main functions are in maintaining the bone matrix and mechanotransdution, a 
mechanism that allows these cells to react to external stimuli, like stress and strain stimuli, 
without disrupting bone homeostasis. Several factors and pathways seem to be involved in 
mechanotransdution, such as the Wnt/β-catenin pathway [2, 13, 14]. When there is a microcrack 
in the bone matrix, osteocytes signal it by undergoing apoptosis and releasing 
osteoclastogenesis stimulation factors, thus promoting bone remodeling [14]. Additionally 
osteocytes can be involved in mineralization and phosphate metabolism, as they can produce 
fibroblast growth factor 23 (FGF23), a protein capable of controlling the reabsorption of 
phosphate in the kidney [15]. 
 
1.3. Osteoclasts and bone remodeling 
Osteoclasts are derived from hematopoietic stem cells (HSC) that can give rise to the 
myeloid and lymphoid lineages. Osteoclasts are derived from the myeloid lineage, and share a 
common progenitor with monocytes, that differentiate into macrophages. The commitment of 
this progenitor into the osteoclast precursors occurs while the cells are still in the bone marrow, 
in the hematopoietic niche. Osteoclast precursors are then recruited to remodeling sites of the 
bone, where the differentiation into mature osteoclasts and fusion into multinucleated 
osteoclasts occurs [3]. Osteoclast differentiation is regulated by the interaction of receptor 
activator of nuclear factor κ-B (RANK), which is expressed on the cell membrane of osteoclast 
precursors and osteoclasts, and its ligand, RANKL (receptor activator of nuclear factor κ-B 
ligand). This interaction is influenced by macrophage-colony-stimulating factor (M-CSF), a 
cytokine that promotes the expression of RANK by these cells; and osteoprotegerin (OPG) (also 
known as osteoclastogenesis inhibitory factor (OCIF), or tumor necrosis factor receptor 
superfamily member 11B (TNFRSF11B)), a member of the TNF family, that acts as a decoy 
receptor for RANKL, thus decreasing its binding to RANK and inhibiting osteoclastogenesis [6, 
16-18].  
Bone homeostasis is maintained by bone resorption and formation, and there are tightly 
coupled mechanisms between the two, as for example inhibition of resorption suppresses bone 
formation [19, 20]. Approximately 5 to 25% of the bone surface is suffering remodeling at any 
given time [1]. The process of bone resorption takes about 3 weeks per site, while bone 
formation needs about 3 to 4 months (Figure 1.1) [21, 22]. Remodeling is important to repair 
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small injuries to the bone tissue, regulate the release of ions, such as calcium and phosphate [1], 
and to promote angiogenesis [23]. 
The remodeling process consists of three consecutive phases, initiation or activation 
phase, transition phase and termination phase [1, 24].  
The initiation phase comprises the recruitment of osteoclast precursors and their 
differentiation into mature osteoclasts, capable of bone matrix resorption. 
The transition phase occurs when osteoclasts activity ceases and coupling mechanisms 
recruit and activate osteoblasts so they can start to produce new bone. Osteoblasts synthesize 
proteins for the bone ECM to form the osteoid, an unmineralized matrix, that will later be 
mineralized due to the calcium binding capacity of said proteins [3]. 
It is considered that the bone remodeling entered the termination phase when bone 
formation by osteoblasts stops and the new bone is fully functional. 
A group of osteoclasts and osteoblasts that cooperates to remodel bone is denominated 
Basic Multicellular Unit (BMU). BMUs are located at the leading edge of a cylindrical canal, in 
cortical bone. At one tip of the cylindrical canal, osteoclasts start bone resorption, giving rise to 
a tunnel, which will be filled by new bone produced by osteoblasts, with the exception of a 
channel in the center. This forms an osteon, or Haversian System, the structural unit of bone. In 
trabecular bone, BMUs are located on bone surfaces, such as the periosteum, forming a hemi-
osteon [25]. 
To achieve bone resorption properties, osteoclasts merge together to form 
multinucleated cells with a large amount of mitochondria, to provide the support for the high 
metabolic activity required by the process. Osteoclasts also have well-developed endoplasmatic 
reticulum and Golgi apparatus placed around each nuclei, as well as a high number of vesicles, 
lysosomes and tubular lysosomes and vacuoles. The presence of this collection of organelles is 
necessary for energy production and protein synthesis for bone resorbing mechanisms [26]. 
Figure 1.1- The bone remodeling process. Recruited osteoclasts are responsible for bone resorption and later for 
recruitment of osteoblast, to initiate bone formation. OS – osteoid. Adapted from [22]. 
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When fully active, mature osteoclasts express several characteristic molecules, such as 
RANK, a cell membrane receptor that activates the nuclear factor-κ B (NF-κB) pathway, 
activating c-jun terminal kinase and thus promoting the expression of osteoclastic proteins, 
leading to osteoclastogenesis [17, 18, 27]; macrophage-colony-stimulating factor receptor 
(M-CSFR), that binds M-CSF to up-regulate the expression of RANK [3]; integrin αvβ3, that 
helps the binding of the cell to the ECM [3, 28]; calcitonin receptor, which binds calcitonin, 
inhibiting osteoclast activity and also a unique marker of osteoblasts that helps differentiate 
them from macrophages [29, 30]; tartrate-resistant acid phosphatase 5b (TRAP-5b), involved in 
organic matrix degradation and present in the vesicles, golgi complex and ruffled border of 
active osteoclasts, this enzyme isoform is also sometimes used to distinguish macrophages from 
osteoclasts, as the formers only produce the TRAP-5a isoform and osteoclasts only express 
TRAP-5b [31, 32]; cathepsin K, that takes part in organic matrix degradation specially collagen 
I, having the same location as TRAP-5b [1]; and matrix metalloproteinase 9 (MPP-9), also 
involved in organic matrix degradation [1, 33]. 
In order to initiate bone resorption, osteoclasts must adhere to the bone matrix, through 
recognition of RGD sequences on bone matrix proteins, such as osteopontin and bone 
sialoprotein [26]. Recognition is performed by integrin αvβ3 and leads to activation of a 
pathway mediated by intracellular tyrosine kinase (Src). Src then acts on focal adhesion kinase 
Pyk2 [34] and proto-oncogene c-Cb1 [35], which contribute for the correct rearrangement of 
osteoclast cytoskeleton. Soriano et al reveled that Src-deficient mice are not capable of 
resorbing bone despite having a high number of osteoclasts [36], likely due to impaired 
osteoclast binding to the bone surface. The recognition by integrin αvβ3 seems to be sufficient 
for osteoclast activation, suggesting that matrix mineralization is not the determining factor for 
osteoclasts to identify their substrate [37]. In fact, a previous study demonstrated that osteoclasts 
can resorb untreated, unmineralized, anorganic or surface-demineralized mammalian dental 
tissues in culture [38], as well as “artificial” substrates like polymeric non-mineralized 
biomaterials [39]. On the other hand, impairment of integrin αvβ3 binding is enough to disrupt 
osteoclastic activity [40, 41].  
Fully active osteoclasts present well-marked cell polarity and characteristic membrane 
regions (Figure 1.2): clear zone (CZ), ruffled border (RB) and basolateral membrane (BLM). 
CZ receives its name from the fact that, on microscope images, it appears as a very light zone of 
the cell, due to the absence of cell organelles. The CZ cytoplasm has a network of actin 
filaments, concentrated on focal contacts, in a ring-like structure. The main functions of the CZ 
are the adhesion of the cell to the bone matrix and the total isolation of the bone resorbing 
compartment from the extracellular fluid and adjacent cells [26]. CZ also occasionally shows 
signals of receptor-mediated endocytosis, suggesting that CZ is involved in endocytosis of 
degraded bone matrix. Additionally, the presence of MT-MMP1 in this region implies that it 
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also has a function in the migration of the cell [42]. The CZ can be immune-identified by 
phalloidin staining of the actin ring [26]. 
The RB has as main goal the resorption of the bone matrix, by dissolution of mineral 
crystals and degradation of proteins. Several enzymes, produced by the complex organelle 
apparatus of osteoclasts, are involved in this process, and are present in vesicles in the RB [26]. 
Carbonic anhydrase, present in the cytoplasm, converts CO
2
 and H2O into HCO3
-
 and H
+
 [43]. 
H
+
 is transported to the Howship’s lacuna, the space formed between the bone face and the 
osteoclast delimited by the RB, by active transport performed by H
+
ATPase in the RB 
membrane. The acidification of the Howship’s lacuna contributes for the dissolution of 
hydroxyapatite crystals and permits the action of enzymes that require acidic conditions [44], 
such as cathepsin K. The ionic balance in Howship’s lacuna is maintained thanks to the passive 
transport of Cl
-
 through CIC-7 channels. Previous studies show that absence of either H
+
ATPase 
or CIC-7 channel is enough to impair bone resorption [45, 46]. Cathesin K, TRAP and MMP-9 
are examples of enzymes responsible for the degradation of the bone organic component, all 
present in Howship’s lacuna. Cathesin K is an enzyme from the cysteine protease family and is 
capable of degrading the triple helix of collagen, the most abundant protein in bone, in acidic 
conditions, being helped by MMP-9 that degrades the segmented collagen fibrils [26]. 
It is believed that the BLM is responsible for the reception of stimulatory cues, such as 
cytokines. Additional functions are the communication with the osteoblasts through direct 
contact and secretion of factors, and transcytosis and exocytosis of degraded bone matrix [33]. 
 
 
 
Figure 1.2 - Mechanism of osteoclast bone resorption. The acidic environment of the Howship’s lacuna dissolves 
the inorganic component of bone, while enzymes like CpK, TRAP and MMP-9 degrade the organic component. The 
action mechanism is similar when degrading biomaterials instead of bone. CZ- clear zone; RB – ruffled border; BLM 
– basolateral membrane; CpK - Cathepsin K; MMP-9 - matrix metalloprotease 9; TRAP - tartrate-resistant acid 
phosphatase. Adapted from [26]. 
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1.3.1. The relation between osteoclasts and macrophages 
Macrophages and osteoclasts derive from the same multipotent precursor of the 
monocyte-macrophage lineage. So, these two cell populations share some characteristics and 
can be transdifferentiated into each other. In fact, osteoclasts can be differentiated in vitro from 
peripheral blood monocytes [47, 48]. Although their functions can differ greatly from each 
other, these cells display histochemical and functional similarities [49]. 
Macrophages are immune cells from the myeloid lineage with an important role in 
maintaining homeostasis, the inflammatory response, and aiding in tissue repair, though 
interaction with other immune cells and phagocytosis of unwanted foreign bodies or damaged 
cells. Macrophages are usually mononuclear cells, but in response to certain stimuli can fuse 
and form multinucleated cells just like osteoclasts, in an attempt to increase their phagocytic 
capacity [19]. Different tissues in our body contain a small population of resident macrophages 
that can act quickly in situations of stress or injury. However, for an efficient response the 
recruitment of blood circulating monocytes to the site of injury and their differentiation into 
mature macrophages is necessary [50]. 
The shared characteristics between macrophages and monocytes include expression of 
CD11b, CD68, TRAP (though different isoforms), MMP-9 and CD61, in slight different levels 
of expression [1, 31-33, 51]. Nevertheless, osteoclasts also display differences from these 
immune cells, such as the very low expression of MHC class molecules, CD14 and receptors for 
immunoglobulin Fc and complement [52, 53]. In addition, macrophages were never described to 
be capable of resorbing mineralized bone, while osteoclasts were never identified as antigen-
presenting cells. 
Recent studies suggest the existence of a myeloid population with specific functions in 
bone, called osteomacs. This special subset of macrophage residing in bone seems to have a 
phenotype with characteristics of both macrophages and osteoclasts, and seem to interact 
closely with the latter and osteoblasts. Absence of the cells nominated osteomacs reduced 
greatly mineralization and production of osteocalcin [54, 55]. Though osteomacs contribution 
for bone remodeling is already being studied, their interaction with biomaterials and even the 
bone cells is still poorly known with contradictory ideas emerging in the field [56]. 
 
1.4. Coupling mechanisms between osteoblasts and osteoclasts 
Coupling bone resorption and formation is regulated by a wide variety of molecules and 
signaling pathways. Osteoblasts (and osteocytes) are capable of recruiting osteoclasts and 
induce their differentiation (Figure 1.3) [57], and in turn, osteoclasts are able to recruit 
osteoblasts and induce their proliferation and differentiation. 
Osteoblasts produce RANKL and M-CSF, important factores for osteoclatogenesis. 
Their presence is enough to induce osteoclast differentiation in vitro. Secreted M-CSF binds to 
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M-CSFR in osteoclast precursors’s membrane 
activating a pathway that will up-regulate the 
expression of RANK. Secreted RANKL acts by 
binding to RANK on osteoclast precursor 
membrane leading to pathways, mediated by 
NF-κB, activator protein-1 (AP-1) and nuclear 
factor of activated T cells c1 (NFATc1), that 
will end in osteoclastic differentiation  [58]. The 
production of RANK by osteoblasts can be 
stimulated by tumor necrosis factor α (TNF-α), 
parathyroid hormone (PTH), interleukin 1 (IL-
1), vitamin D3, prostaglandin E2, among some 
other cytokines/hormones/growth factors [1, 58], 
which means that these regulate osteoclast 
differentiation indirectly. Wnt5a signaling by 
osteoblasts is another way to promote 
osteoclastogenesis [59].  
Besides producing factors that stimulate osteoclastogenesis, osteoblasts are also capable 
of producing one factor capable of limiting it, in order to preserve bone homeostasis, 
osteoprotegerin (OPG). OPG acts as a decoy receptor for RANKL, competing directly with it 
and so inhibiting its signaling on osteoclasts [1]. 
Moreover, osteocytes also regulate osteoclast differentiation, as dying osteocytes in 
damage sites send chemical signals to osteoblasts in order to produce more RANKL [60] and it 
seems that osteocytes themselves are capable of producing it [61]. 
Osteoclasts are, in turn, also involved in regulation of osteoblast differentiation, 
proliferation and function, especially during the transition phase. The degraded bone matrix 
releases factors such as TGF-β, IGFs and BMPs that have been shown to influence osteoblastic 
differentiation [1]. However, non-bone related signals produced by osteoclasts can also induce 
bone formation, as a previous study indicated that conditioned media from osteoclasts cultured 
on plastic surfaces, instead of bone surfaces, also had a significant impact on increasing 
mineralized matrix formation in vitro [62]. Recruitment of MSC or osteoblasts from other sites 
can also be promoted by osteoclasts. Osteoclasts produce PDGF-BB, suspected to have a role in 
osteoblasts chemotaxis [63]. Non-resorbing osteoclasts at the site of remodeling, instead of 
becoming active, secrete factors that will induce the up-regulation of osteogenic markers and 
recruitment of MSC [6]. A study by Zhao et al. showed that reverse signaling of EphrinB2, a 
ligand for Src receptor, in osteoclast precursors inhibited osteoclast differentiation and that 
forward signaling of EphB4, a receptor for Src, in osteoblasts induced osteogenic 
Figure 1.3 - Regulation os osteoclast differentiation 
and function by osteoblasts. Osteoclast 
differentiation is induced by RANKL and M-CSF 
produced by osteoblasts. Factores like PTH, vitamin 
D3 and IL-1 up-regulate the production of RANKL, 
thus indirectly promoting osteoclast formation. 
Osteoblasts are also capable of decrease osteoclast 
differentiation and function thorugh the secretion of 
OPG. RANK - receptor activator of nuclear factor κ-
B; RANKL – RANK ligand; M-CSF - macrophage-
colony-stimulating factor; M-CSFR – M-CSF 
receptor; OPG -  osteoprotegerin; PTH - parathyroid 
hormone; IL-1 – interleukin 1. Adapted from [57]. 
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differentiation, proving the existence of a bidirectional signal between osteoclasts and 
osteoblasts [64]. 
Immune cells are capable of producing factors that interact with bone cells [65]. 
Macrophages and osteoclasts share the same precursor and some regulatory molecules 
(transcription factors, cytokines, membrane receptors) that are able to influence each other [20], 
suggesting that can exist cross-talk between these cells. A study reported that mice deficient in 
some immunomodulatory molecules also presented an abnormal osteoclast phenotype [66]. 
T-cells produce TNF-α and RANKL that up-regulate osteoclastogenesis and core binding factor 
1, which is involved in osteoblast development. Because immune cells and osteoclasts share the 
same origin, start differentiating in the same environment and secrete molecules in the blood 
circulation, it is considered that they can influence each other both at the beginning of their life 
cycles and after differentiation [67]. Some other examples of molecules produced by immune 
cells that can interact with osteoclasts are IL-1, IL-4 and Interferon-γ [68]. Immune cells can 
also interact with osteoblasts. For example, macrophages are capable of promoting 
osteoblastogenesis by secretion of IL-18 [69]. As the immune system seems to have a close link 
with the bone system, deregulation of one of them can lead to deregulation of the other: 
osteopetrosis, a bone disease, can lead to decrease of the capacity to combat infection while 
auto-immune responses can lead to bone diseases such as arthritis rheumatoid [21]. 
Most studies regarding bone regeneration are focused on osteoblasts, as these are the 
cells responsible for new bone formation. However, considering the importance of bone 
resorption in bone regeneration, osteoclasts are likely as important to this process, as 
osteoblasts. Hence the growing number of reports studying the interaction between these two 
populations of cells, either by co-culture or culture with conditioned media [70]. Despite that, 
most studies continue to focus on the influence of osteoblasts on osteoclasts [71-74], with the 
opposite direction of signals, osteoclast to osteoblast [75], still being less explored. 
It is necessary to uncover more about the interactions that osteoclasts have with others 
relevant cells, drugs and biomaterials, in order to develop more efficient new therapies to treat 
the increasing number of bone diseases. 
 
1.5. Bone diseases and therapies 
Bone diseases can be caused by a deregulation of the bone remodeling process, which 
can happen due to old age, hormonal alterations, physical activity changes, medication drugs, or 
as a consequence of disease. When bone resorption occurs at a higher rate than bone formation, 
the skeleton can present an overall fragility caused by lack of adequate structure. This can give 
rise to bone fractures, as a 10% decrease in bone mass is describer to double the risk of fracture 
[21]. The most common and widely studied bone fragility disorder is osteoporosis, which occurs 
most frequently in women after menopause, because of the decrease of estrogen due to the end 
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of the fertile life. Estrogen has receptors in both osteoblasts and osteoclasts and it is known to 
influence bone turnover. The low concentration of estrogen, along with the low concentration of 
some other steroids, induces an increase in the number of osteoclasts, resulting in unbalanced 
bone resorption. Decreased concentrations of these molecules have systemic effects, interfering 
with the function of other organs besides bone. So, it became common practice to give women 
in menopause an oral supplement of estrogen, to compensate for its absence, minimizing effects 
in the body, including on bone tissue preservation [76]. Osteoporosis can also be a consequence 
of other diseases, such as multiple myelomatosis, hyperparathyroidism or hyperthyroidism. In 
this case the best treatment is to treat the original condition, to eliminate the source of the 
problem [21]. 
Bisphosphonates have been used as a treatment for diseases related with excessive bone 
resorption for more than four decades. Bisphosphonates can inhibit osteoclast activity by 
entering the osteoclast and deregulating its metabolism, and potentially inducing apoptosis. It is 
a method that not only inhibits osteoclasts but also reduces their numbers, without being 
specific of any disease [77]. 
On the other hand, excessive bone formation can also result in disease, of which the 
most common example is osteopetrosis. In this condition, osteoclast failure leads to 
accumulation of bone, which in turns leads to complications such as reduction of bone marrow 
size (with a big impact on hematopoiesis, which can give rise to anemia and high susceptibility  
to infections) and compression of nerves and blood and lymphatic vessels (causing premature 
bone necrosis, infections and anemia). One of the treatments for this disease is the 
transplantation of HSC to both attenuate the symptoms and trying to increase osteoclast number 
and activity. However, this approach has a very low success rate [78]. 
Diseases of bone metabolism, where the activity of osteoblasts and osteoclasts is 
deregulated also result in bone problems. As an example, Paget’s disease is characterized by an 
excessive osteoclastogenesis with inherent increase in bone resorption that is followed by 
promotion of osteoblastic activity and bone formation, as the body’s attempt to compensate the 
bone loss. This ultimately results in the formation of defective enlarged bones (plexiform bone) 
that lacks the right structure and thus is susceptible to bowing, fractures and deformities. Paget’s 
disease’s cause seems to be a set of mutations that lead to excessive promotion of bone 
resorption caused by infection of virus from the paramyxovirus class [21, 79]. Renal 
osteodystrophy is another condition that leads to bone remodeling deregulation: it is a 
consequence of end-stage renal disease characterized by reduced bone mineralization and 
increased bone resorption, with implications on the whole bone system [80]. 
Some cancers have a tendency to form metastases in bone. Breast and prostate cancers 
are the ones that show a higher rate of bone metastases. In these cases, bone resorption is 
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enhanced to give the tumor more space to grow, which results in a formation of a structure that 
does not have the adequate characteristics to maintain bone functions [77]. 
Finally, inflammatory diseases can lead to bone remodeling imbalance, as expected 
from the large interactions that the immune cells are reported to have with bone cells. 
Rheumatoid arthritis is a disease where immune cells, like T lymphocytes, monocytes and 
macrophages become deregulated, increasing in number and secreting an excess of 
osteoclastogenesis stimulating factors, as the pro-inflammatory cytokine IL-17 or the 
osteclastogenesis promoter RANKL. The excessive osteoclastogenesis leads to augmented bone 
resorption that causes destruction of articular cartilage tissue and bone erosion by chemical and 
mechanical stresses [21]. 
Most treatments for bone diseases focus on the reduction of bone resorption by 
osteoclasts, the main common feature of most of these disorders. Along with the administration 
of estrogen supplements and bisphosphonates, injections of other osteoclast activity inhibitors 
are widely used. Calcitonin strongly inhibits bone resorption, however it can cause hormone-
induced resistance, so it is not an ideal method [21, 29]. PTH administration seems to promote 
bone formation, so it is an alternative therapy focusing on counteract the diseases effects. 
Although it may seem strange that a hormone that actually promotes bone resorption is used to 
combat bone loss, studies show that intermittent and low doses are efficient in stimulating 
osteoblast activity, maybe due to cross-talk between these cells and osteoclasts [81]. The 
already mentioned osteoprotegerin (OPG) is another candidate for alternative therapies, since its 
original goal is the very inhibition of bone resorption. However, due to potential immune 
reaction and side effects related to repeated use, this complex protein is not one of the most 
promising options [21]. 
In 2008, a new approach was suggested by Bonnelye et al. that concluded that strontium 
ranelate has an influence in reducing bone resorption, by inhibiting osteoclast differentiation 
and function, and in stimulating bone formation, by promoting osteoblast differentiation. This 
means that this molecule has the potential to not only decrease the impact of excessive 
osteoclast activity, the cause of the problem, but also to promote healing of the damaged sites, 
by stimulating osteoblasts [82]. However, randomized placebo-control studies showed that this 
substance increased the risk of venous thromboembolism. During the post-marketing 
surveillance, DRESS syndrome, a severe dermatological reaction, and an increase in pulmonary 
embolism and myocardial infarction risks were reported. These side effects have limited the oral 
use of strontium ranelate to patients who do not respond to other medicines, and when the risk 
of bone fracture greatly overwhelms the cardio-vascular risk [83]. 
Many other molecules involved in the bone remodeling process have the potential to 
become drugs in new therapies. Both for these and for the ones already in use, directing the 
therapeutic molecule to the desired site instead of allowing its free circulation in the body, can 
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decrease side effects and potentiate the desired effect. Examples of approaches for directing 
molecules in vivo are the use of biomaterials and genetic therapies [21]. 
 
1.5.1. Biomaterials for bone applications 
Extensive bone damage (e.g. non-union fractures, simple large fractures, bone defects or 
deformities) can arise from bone disease or trauma. While small defects or systemic conditions 
are usually treated using one of the therapeutic approaches discussed above, treatment of large 
defects usually involves surgery for providing bone or joint stabilization, or even replacement. 
The gold standard in bone implants is the autologous graft material (bone from the patient), as it 
has complete histocompatibility and all the properties of bone. Its main limitations are high 
donor-site morbidity and limited availability. Allografts are an alternative solution with the 
same bone characteristics. However, it is not completely histocompatible, is more expensive, 
has more processing, sterilization and storage problems, and can lead to disease transmission 
[84]. 
Nonetheless, the most used materials in orthopedic surgery are still the classic 
bone/joint replacement implants. Composed of metal alloys, ceramics and high density 
polymers, these biomaterials are designed to be “inert”, so as to avoid implant rejection. 
However, they present several drawbacks, like the generation of biomaterial-derived wear and 
corrosion debris, leading to a chronic inflammatory response, accompanied many times by the 
formation of a fibrous capsule around the implant. Accelerated bone resorption at the site of 
implant potentiated by the chronic inflammation then mostly leads to aseptic loosening and 
pain, requiring a revision surgery with implant substitution. This topic has been recently 
reviewed [85]. In order to overcome these current limitations, research is focused on the 
development of new biomaterials with or without pre-encapsulated cells (MSC or osteoblasts), 
capable of substituting or helping autologous grafts or allografts, in promoting bone 
regeneration [84]. 
In this context, biomaterials designed for bone repair should support and promote the 
bone remodeling process and combine good resorptivity with osteoconductivity (ability to 
promote vascular growth and allow free proliferation of bone cells) and osteoinductivity (ability 
to promote osteoblastic differentiation and new bone formation) [86-88]. 
New biomaterials currently being investigated for bone repair/regeneration applications 
include metals, ceramics, bioactive glasses, cements, composites and polymers The interaction 
of osteoclasts with these biomaterials was studied only to a limited extent, with most of the 
attention being devoted to osteoblasts [89]. 
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1.5.1.1. The use of fibrinogen to promote bone regeneration  
Fibrinogen (Fg) is a blood plasma protein, involved in blood coagulation. It is converted 
into fibrin by the action of thrombin in the presence of ionized calcium. Fg is synthetized in the 
liver by hepatocytes. Studies show that Fg is required for normal platelet function and wound 
healing [90]. Fg structure contains two RGD sequences, important for cell adhesion, as 
fibrinogen/fibrin forms a network in the site of injury that will act as a foundation for tissue 
regeneration [91]. Also, Fg promotes cytokine secretion by peripheral blood mononuclear cells 
(PBMC), suggesting that it can contribute to the inflammatory process [90]. 
It was reported that Fg may have an important role in tissue repair, by stabilizing wound 
fields and supporting local cell proliferation and migration of inflammatory, endothelial and 
stromal cells [92]. It may also have an important role in angiogenesis at injury site, as it has a 
great binding affinity to vascular endothelial growth factor (VEGF) [93]. Fg was previously 
used in tissue regeneration, for urinary tract regeneration [94] and reconstruction of blood 
vessels [95]. Fg or composite biomaterials containing Fg were also studied regarding cellular 
migration, proliferation and morphological and functional changes of several types of cells [96], 
such as smooth muscle cells [97, 98], MSC [99] and fibroblasts [100, 101]. Fibrin, a protein 
resulting from the action of thrombin on Fg, was already studied in the context of wound 
healing in the cardiovascular system [102-104] and in the nervous system [105, 106], as well as 
for MSC transplantation [99]. Scaffolds of fibrin were used in a rabbit bone model, suggesting 
its potential to help regenerate small bone injuries [107]. Another study envolving MSC and a 
composite biomaterial containing fibrin suggests that bone defects correction can be performed 
in a minimally invasive technique [108]. Adsorbed fibrin on polycaprolactone/ poly(glycolic 
acid) (PCL/PGA) hidrogels increased the mineralization and bone formation when compared 
with PCL/PGA hidrogels alone [109]. Importantly, a study by Peled et al. reported that 
poly(ethylene glycol) (PEG) conjugated with Fg materials have potential osteogenic properties 
in a tibial bone defect model [110]. A more recent study from our team shows that chitosan 
porous scaffolds modified with Fg lead to enhanced bone formation in vivo than chitosan-only 
scaffolds, while stimulating angiogenesis and correlating with differences of the systemic 
immune response [111]. Macrophages respond to adsorbed Fg by up-regulating angiogenic and 
osteogenic soluble factors [112]. A study showed that a Fg hydrogel supplemented with BMP-2 
had a positive impact on bone regeneration [113]. 
 
1.6. Osteoclasts in new biomaterials research 
Assessing in vitro the osteoclastogenesis process is possible, although it is still hard to 
compare quantitatively osteoclastic resorption in different models, due to lack of standardized 
systems to evaluate their behavior on biomaterials [89]. Dentine and cortical bone slices are 
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used as substrates for investigating the mechanisms of osteoclastogenesis in vitro, as well as for 
studying the therapeutic profiles of medication drugs [114, 115]. 
Several parameters of the biomaterials can influence osteoclastic activity [89], but 
biomaterial’s chemical composition is considered one of the most important factors. For 
example, the presence of RGD or other anchoring sequences is essential for adhesion to the 
substrate and initiation of resorption [26]. The chemical dissolution and/or cellular resorption 
rates been proposed to determine to a large extent the success of the biomaterial in bone 
regeneration, as they should be synchronized with bone formation [89]. The mineral density is 
inversely proportional to the rate of osteoclastic activity [116]. Surface characteristics, like 
roughness, pore size and interconnection and wettability, modulate osteoclasts [89]. Surface 
roughness plays an important role on osteoclast behavior, as it was reported that monocyte to 
osteoclast differentiation could be promoted by smoother surfaces, which can be explained by 
the enhanced possibility of cell spreading in low roughness surfaces [117]. Pore size and 
interconnection are important parameters that affect the biomaterial potential to promote cell 
migration and blood vessel formation for irrigation of new bone. So, macro-porous materials, or 
scaffolds, are believed to be the best structures to enhance bone repair  [89]. Wettability, or 
surface energy, influences cell adhesion, with cells preferring high-energy surfaces, such as the 
one presented by hydroxyapatite crystals of bone matrix [118]. 
Although polymers, and specifically polymeric biological molecules (biopolymers), are 
reported to have great potential for tissue regeneration, due to their enhanced biocompatibility 
and biodegradability, research involving them and osteoclasts is scarce [89]. Collagen, naturally 
present in the body, was studied as a coating for polydimethylsiloxane, resulting in an increase 
of osteoclastic activity [119]. In another study, monocytes were allowed to differentiate into 
osteoclasts by stimulation with RANKL and M-CSF on fibroin, chitosan and poly(L-lactic acid) 
(PLLA) substrates. The number of TRAP-positive cells was higher on the first two substrates, 
suggesting that these promoted osteoclastogenesis more efficiently [120]. In a recent study, the 
formation of multinucleated osteoclasts was analyzed on chitosan and fibrinogen-modified 
chitosan surfaces. Both substrates showed multinucleated osteoclast formation, however the 
presence of adsorbed fibrinogen led to a significantly higher number of more multinucleated 
osteoclasts, and enhanced their activity, suggesting that fibrinogen-modified materials may be 
resorbed by osteoclasts [39]. Importantly, both soluble and adsorbed Fg seem to potentiate 
osteoclast fusion, leading to a higher number of mature osteoclasts available for bone 
regeneration [39, 121]. However, soluble Fg is correlated with a chronic inflammatory process 
[121, 122]. On the other hand, as discussed above adsorbed Fg on chitosan films leads to 
enhanced osteoclastogenesis and overall biomaterial performance, compared to chitosan-only 
[39]. 
Can osteoclast pre-conditioning enhance osteogenic differentiation of MSC: a 3D in vitro study with Fg scaffolds 
15 
 
Thus, in the current work the potential of Fg-only scaffolds for promoting bone 
regeneration will be investigated by examining their capacity to promote osteoclast 
differentiation and activity. 
 
1.7. Aims  
In the context of what was discussed above, the main aim of this work was to evaluate 
human primary monocyte-derived osteoclast differentiation and function in 3D Fg scaffolds, 
having monocyte-derived macrophages as a control. 
To accomplish that aim, four specific objectives were delineated: 
1- Produce and characterize the structure of Fg-3D scaffolds. 
2- Culture monocyte-derived macrophages and OC in presence of FG-3D extracts 
and directly on the scaffolds, evaluating cell morphology and specific markers of osteoclast 
differentiation and activity.  
3- Assess the capacity of macrophages and OC to degrade Fg-3D scaffolds. 
4- Investigate the potential for conditioned media from OC, differentiated on Fg-   
3D scaffolds, to promote MSC osteogenic differentiation. 
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2. Materials and Methods  
 
2.1. Production of fibrinogen 3D scaffolds (Fg-3D) 
For preparation of Fg scaffolds a protocol adapted from [111, 123] was used. Briefly, 
human Fg (fraction I, type III from human plasma; F3879 from Sigma) was dissolved in warm 
PBS at 60 mg/mL under magnetic agitation and cast in 48-well plates (800 µL per well). The 
plates were frozen at -20ºC and freeze-dried at -80ºC for 48 h. The scaffolds were removed from 
the wells and stored in the dark in a desiccator at room temperature until they were cut with 
appropriate cutters/molds into cylinders with 4 mm diameter and 2.5 mm height for use in the 
experiments. Before cell seeding, the scaffolds were neutralized, disinfected and hydrated, in 
sterile conditions and under vaccum, with a gradient of ethanol solutions (96% for 10 min, 70% 
for 30 min, 50% and 25% for 10 min each) and PBS (three times for 10 min). Prior to cell 
seeding, each scaffold was placed in the center of a well of a 96-well plate and allowed to 
incubate at 37ºC in complete cell medium for at least 1 h [124]. 
 
2.2. Monocytes isolation 
Human monocytes were isolated by negative selection from buffy coats from healthy 
blood donors, kindly donated by Serviço de Imunohemoterapia, Centro Hospitalar de São João, 
Porto, using a method adapted from [125]. Briefly, the buffy coats were centrifuged at 1200 g 
for 35 min, with no acceleration or brake. Gradient separation formed three layers and the 
middle layer, enriched in PBMCs, was collected. RosetteSep™ Human Monocyte Enrichment 
Cocktail (StemCell™) were added, 67µL per mL of PBMCs, and incubated for 20 min at RT 
under orbital agitation. This suspension was then diluted 1:1 in 2% FBS in PBS, carefully 
transferred to a new tube, and overlaid on 1 volume of Histopaque and centrifuged at 1200 g for 
35 min, with no acceleration or brake. Three new layers were formed and the middle layer, 
enriched in monocytes, was collected and washed with PBS and centrifuged at 700 rpm for 17 
min, to remove platelets, until the supernatant was clear. The cell pellet was resuspended in 
complete medium (RPMI supplemented with 1% P/S, 1% glutamine and 10% FBS) and the 
number of viable cells was counted using the exclusion dye trypan blue. 
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2.3. Monocyte culture in 2D in the presence of fibrinogen or Fg-3D extracts 
For the preparation of the Fg extract, 10 mg of Fg-3D scaffolds were incubated in 10 
mL of α-MEM (1% P/S, without FBS) at 37ºC for 24 h, under agitation (120 rpm) (ISO 
10993-5:2009 standard). After incubation time, supernatant was collected, filtered through 0.22 
µm filters and stored at -20ºC until use. For obtaining the desired concentrations, Fg extract was 
diluted in α-MEM and 10% FBS was added. Prior to cells seeding, coverslips were placed in the 
bottom of 24 well plates and left uncoated or coated by adsorption of fibrinogen (100 µg/mL) 
for 1 h, before being washed twice with PBS. Monocytes (2.5x10
5
 cells per well) were cultured 
with RPMI supplemented with 1% glutamine, 1% P/S and 10% FBS, for macrophage 
differentiation; or α-MEM supplemented with 10% FBS, 50 ng/mL RANKL and 30 ng/mL 
M-CSF, for osteoclast differentiation [39]. Four conditions were studied: basal media only, 
fibrinogen adsorbed to the coverslip with basal media, and basal media with two concentrations 
of fibrinogen extract (50% and 25%). Media was changed twice a week. Cells were kept in 
culture for 7 days (macrophages and osteoclasts) and 21 days (osteoclasts). 
 
2.4. Monocytes seeding and differentiation into osteoclasts or macrophages on 3D 
fibrinogen scaffolds 
A total of 1x10
6
 cells, in 10 µL of complete medium, were seeded on each scaffold and 
incubated at 37ºC for 2 h. Monocytes were allowed to differentiate into macrophages, or 
differentiated into osteoclasts as described above, and in [39]. Media was changed twice a week 
and collected, as conditioned media. Conditioned media for each week (week 1 – up to day 7; 
week 2 – days 8 to 14; week 3 – days 15 to 21) of culture was pooled for each condition, 
centrifuged at 14000 rpm for 5 min and the supernatants were transferred to new tubes and 
stored at -20ºC until further use. Scaffolds without cells, but incubated in either media were 
used as controls. 
 
2.5. MSC culture 
Bone marrow MSC (mesenchymal stromal cell) had been isolated and characterized to 
follow the international stem cell society criteria, as described [126]. For MSC culture and 
maintenance, the cells were placed in flasks with DMEM (low-glucose with glutamax) 
supplemented with 10% FBS Hyclone and 1% P/S. Media was changed twice a week. Cells 
were passaged at 80% confluence. Medium was removed and the flasks washed twice with 
warm PBS. Trypsin EDTA was added to the flasks and allowed to act for 5 min at 37ºC. 
Trypsin was then inhibited with complete medium and cells were transferred to a tube and 
centrifuged at 300 g for 10 min. The viable cells were counted using trypan blue and plated at a 
density of 3000 cells/cm2. 
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2.6. Morphological analysis by SEM 
For observation of cell behavior on the fibrinogen structure, as well as the influence of 
the cells and time of culture in the scaffold itself, cells were fixated at 7, 14 and 21 days of 
culture. Scaffolds without cells were incubated in α-MEM or RPMI for 21 days. Media was 
removed from the wells, the scaffolds were washed twice with warm PBS for 5 min under 
orbital agitation and fixated with a solution of 2.5% glutharaldehyde in 0.1 M sodium 
cacodylate for 30 min under agitation. The scaffolds were washed three times with 0.1 M 
sodium cacodylate, dehydrated in a series of ethanol (50%, 60%, 70%, 80%, 90% and 99%, for 
10 min each) under orbital agitation and stored in absolute ethanol at 4ºC until being critically 
point dried and mounted on an appropriate support using araldite glue. Dry and neutralized 
scaffolds were also prepared. Samples were then sputtered with a gold and palladium mixture, 
before being observed under a Scanning Electron Microscope (FEI Quanta 400FEG ESEM / 
EDAX Genesis X4M) at CEMUP (Porto). 
 
2.7. Nuclei and cytoskeleton staining for confocal microscopy 
Cells after 7, 14 and 21 days of culture were stained for f-actin and nuclei. Media was 
removed from the wells and the samples were washed twice with warm PBS for 5 min, fixed 
with 4% PFA (paraformaldehyde) at room temperature for 15 min and washed again twice with 
PBS (1X1 min, 1X15 min), always under orbital shaking. For cell membrane permeabilization, 
cells were incubated for 15 min with 0,2% Triton X-100 in PBS and washed three times with 
PBS for 5 min, under agitation at room temperature. For blocking non-specific binding, samples 
were incubated with 1% BSA at 37 ºC for 1 h under agitation and washed again with PBS for 5 
min, twice. After that, the samples were incubated at 37ºC for 1 h with a 16:1000 solution of 
AlexaFluor 488 conjugated phaloidin in PBS (supplemented with 5mM of EGTA and MgSO4) 
and washed three times with PBS for 5 min under agitation. All incubation steps were 
performed in the dark. The samples were stored in Flouromount with DAPI at 4ºC until 
observation in the confocal microscope (Leica SP2 AOBS). Images were taken with Leica 
Confocal Software and processed with Fiji (ImageJ). 
 
2.8. Cathepsin K staining for confocal microscopy 
After 21 days of culture, the samples were fixed with 4% PFA, permeabilized and 
blocked as described in the previous subsection. Then the samples were incubated for 2 h with 
anti-cathepsin K rabbit polyclonal IgG antibody, 1:100 in PBS, in the dark and under agitation. 
After incubation, the samples were washed three times with PBS for 5 min under agitation and 
then incubated for 1 h with a solution of AlexaFluor-647 conjugated secondary antibody anti-
rabbit 1:200 in PBS and AlexaFluor-488 conjugated phaloidin 16:1000 in PBS (supplemented 
with 5mM of EGTA and MgSO4). All incubation steps were performed in the dark. The 
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samples were stored in Flouromount with DAPI at 4ºC until observation in the confocal 
microscope (Leica SP2 AOBS). Images were taken with Leica Confocal Software and 
processed with Fiji (ImageJ). 
 
2.9. Metabolic activity quantification on 3D fibrinogen scaffolds 
Macrophages and osteoclasts were differentiated on fibrinogen scaffolds as described 
before. At 7, 14 and 21 days, a resazurin assay was performed to quantify the metabolic activity 
of the cells present in the scaffold. Briefly, a dilution of 1:10 of a resazurin solution (0.1mg/mL) 
in appropriate culture medium for each type of cell was added to the wells and the samples were 
incubated for 2 h. After incubation time, the medium was collected, 100 µL was transferred to a 
well of a black 96-well plate (triplicates were made) and the intensity of fluorescence at 590 nm 
after excitation at 530 nm was read using a microplate reader (Biotek – Sinergy HT). 
Quantification of total DNA present in the sample was performed, as described bellow, in order 
to normalize the results by number of cells. 
 
2.10. DNA extraction and quantification 
After the resazurin assay, the media were collected and the scaffolds were washed twice 
with warm PBS. To collect the cells from the scaffolds, PBS was aspirated, trypsin EDTA was 
added and the plate was incubated at 37ºC for 30 min at 70 rpm. Then complete culture medium 
was added and the mixture was transferred to eppendorfs and centrifuged at 300 g for 5 min at 
4ºC. The supernatant was discarded and the pellet was ressuspended in 50 µL Triton X-100 1% 
(v/v) in PBS and stored at -20ºC until quantification. 
For DNA quantification, Quant-iT PicoGreen dsDNA Assay Kit (LifeTechnologies, 
Thermo Fisher Scientific) was used according to manufacturer’s instructions. The samples 
stored in Triton X-100 1% (v/v) at -20ºC were allowed to thaw at 4ºC for 1 h under orbital 
agitation (30 rpm). 450 µL PBS were added to each sample, homogenized and centrifuged  at 
10000 g for 15 min at 4ºC. The supernatant was transferred to new eppendorf tubes and 10 µL 
of the sample an 90 µL of TE Buffer were transferred to a black 96-well plate (duplicates were 
made). Then 100 µL of PicoGreen® solution was added to each well and the plate was 
incubated for 5 min in the dark. Fluorescence was read a fluorimeter (Biotek – Sinergy HT) 
(λexcitation = 480 nm, λemission = 520 nm) and the quantity of DNA was calculated through 
calibration curves. 
 
2.11. TRAP staining 
After 21 days of culture, the samples were assessed for the presence of TRAP positive 
cells using the Leukocyte Acid Phosphatase (TRAP) kit (from Sigma) according to the 
manufacturer’s instructions. After being fixed with a citrate/acetone solution for 30 s and 
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washed with ultrapure water, the samples were allowed to dry for 15 min. A solution containing 
Tartrate, Naphtol AS-BI Phosphoric Acid and Acetate was filtered through 15 µm filters and 
warmed at 37ºC before being added to the wells with the samples and incubated for 1 h in the 
dark at room temperature, under orbital agitation. Then, samples were washed with distillated 
water and stained with acid hematoxylin for 5 min. A solution of acid in ethanol (1% v/v) was 
used to remove excess of hematoxylin staining. The samples were allowed to dry and observed 
using a stereomicroscope (Olympus). 
 
2.12. Measuring the scaffold area along time  
Scaffolds with osteoclasts, macrophages and without cells were prepared. After 7, 14 
and 21 days, the samples were fixated with 4% PFA as described before. The samples were 
observed with a stereomicroscope (Olympus) and the images were analysed with Fiji (ImageJ). 
 
2.13. MSC osteogenic differentiation on Fg-3D 
MSC were used in passages 5 and 6. A total of 70x10
3
 cells, in 10 µL of complete 
medium, were seeded on each scaffold and incubated at 37ºC for 2 h. After that time, 200 µL of 
medium was added to each well. Three controls were used: positive control (osteogenic 
medium: DMEM with 10% FBS, 1% P/S, 100 mM dexamethasone, 0.05 mM ascorbic acid and 
10 mM β-glicerophosphate), negative control (basal medium: DMEM with 10% FBS and 1% 
P/S) and cytokine control (medium with osteoclast differentiating cytokines: medium used for 
osteoclastic differentiation diluted 1:1 in basal medium). Conditioned media from week 1, 2 and 
3 of culture with osteoclasts, from 4 different donors and with macrophages from 2 different 
donors, were diluted in basal medium 1:1. Duplicates were made for each condition. Media was 
changed twice a week. Cells were fixed with 4% PFA as described before at day 14. After 
fixation, cells were incubated for 45 min at room temperature with ALP substrate (4% Naphtol 
AS-MX phosphate alkaline solution in Fast Violet B solution (from Sigma)). Samples were 
washed twice and kept in PBS. Samples were observed and photographed with a 
stereomicroscope (Olympus) and analyzed using Fiji (imageJ) and Matlab: ALP intensity was 
counted after thresholding colour images on the total area of each well and quantified as 
previously described by us (ALP: red > 76; red > 1.1 x green;  green  <  1.12 x blue) [127]. 
 
2.14. TGF-β1 and D-dimer quantification 
Conditoned media and where indicated supernatants from the degraded scaffolds were 
used to quantify Transforming growth factor β1 (TGF-β1) and the D-dimer Fg degradation 
product. TGF-β1 concentrations were measured using Quantikine ELISA Kit for human 
TGF-β1 (R&D Systems, USA), according to the manufacturer's protocol. Cytokine 
concentration was calculated against a standard curve. To measure scaffold degradation over 
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time of culture, quantification of D-dimer in the conditioned media was performed using 
RayBio® Human D-Dimer ELISA Kit according to manufacturer’s instructions. A calibration 
curve using standards was used to quantify the amount of d-dimer in each sample. 
 
2.15. Statistical analysis 
Statistical analysis of the results obtained was performed using GraphPad Prism 6 
(GraphPad Software, Inc.). Data was tested for normality using D’Agostinho and Pearson 
omnibus normality test. For parametric samples, ANOVA test was performed followed by 
Tukey’s for multiple comparison. When samples were non-parametric, the Kruskal-Wallis test 
was performed, followed by Dunns, for multiple comparisons. A value of p<0.05 was 
considered statistically significant.  
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3. Results 
Fg-3D scaffolds were developed in our team to be used for bone regeneration. In the 
current work we investigated their indirect and direct effect on the differentiation and activity of 
primary monocyte-derived macrophages and OC. 
 
3.1. Fg-3D structure is modified by culture media 
The impact of neutralization with an ethanol gradient and incubation with cell culture 
media on Fg-3D morphology was evaluated by electron microscopy. SEM analysis revealed that 
the overall structure of dry Fg-3D was similar to that obtained for chitosan materials [111], and 
Fg scaffolds [124] previously prepared in our lab (Figure 3.1A). The structure of the scaffold 
characterized by an interconnected porous network was largely maintained upon neutralization 
and stabilization with an ethanol gradient (Figure 3.1B). When incubated in culture media for 
21 days Fg-3D structure presented minimal changes in α-MEM (Figure 3.1C), while in RPMI 
scaffolds showed a more degraded structure where pores are not always interconnected and 
some walls appear to have collapsed (Figure 3.1D).  
 
 
 
 
 
 
 
 
 
 
 
 
  
A B 
C D 
Figure 3.1 - Structure of Fg-3D scaffolds is altered by incubation in culture media. A dry scaffold (A), a 
neutralized scaffold (B) and scaffolds incubated with α-MEM (C) or RPMI (D) for 21 days were observed using 
SEM. Scale bar=200 µm. 
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3.2. Fg-3D extracts are cytotoxic to primary macrophages and osteoclasts 
In order to investigate the biological action of Fg materials, we started by looking into 
the effect on primary human monocyte-derived macrophages and osteoclasts, of prolonged 
exposure to Fg-3D degradation products. Cells were seeded on glass coverslips, and incubated 
with different concentrations of Fg-3D extracts for 7 days, as a control cells were also cultured 
on Fg films. Cell morphology and expression of catepsin K were evaluated. The results obtained 
are illustrated in Figure 3.2A, and showed that while in basal and adsorbed Fg conditions cells 
present similar morphologies, when cultured with Fg extracts, the viability of both macrophages 
and osteoclasts was greatly reduced. In presence of 25% extract, there were fewer cells, that 
were smaller and less spread than those in the control. When 50% extract was used, none to 
very few cells were observed for either macrophages or osteoclasts. 
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A 
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Figure 3.2 - Fg extracts decrease viability of primary macrophages and osteoclasts.  Osteoclasts  and 
macrophages  were cultured on uncoated coverslips with complete media (Basal), or on Fg-coated coverslips, with 
complete media (Adsorbed Fg), or with Fg extracts (E) diluted in complete medium, as indicated (25% and 50%). 
Cells were fixed and stained for cytoskeleton (green), nuclei (blue), and cathepsin K (red). Z-projections of 
macrophages and osteoclasts at 7 days (A), and z-projections (top row) and medial sections of the Z-stacks (bottom 
row) of osteoclasts at 21 days (B) Images are representative of 3 independent experiments. Scale bar=50 µm. E-
extract; Mac-macrophages; OC-osteoclasts. 
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 Nonetheless, osteoclast cultures were maintained until day 21 (Figure 3.2B), with cells 
in presence of 25% of extract remaining viable but presenting significant morphological 
changes. Cells remained mononucleated with a fusiform morphology, instead of the round 
multinucleated osteoclasts characteristic morphology, that was visible in the controls with or 
without adsorbed Fg. Interestingly, osteoclasts stained positive for cathepsin K at day 21, even 
in presence of 25% extract, indicating that the few cells that remain were able to differentiate 
(Figure 3.2B). This staining was specific, as neither the negative control nor the cells at 7 days 
presented any red staining (Annex 1).  
 
3.3. Osteoclast and macrophage differentiate on Fg-3D scaffolds 
The potential of Fg-3D to support osteoclasts and macrophage differentiation was 
evaluated by culturing monocytes directly in Fg-3D. Cells metabolic activity in Fg-3D was 
assessed at days 7, 14 and 21 of culture. Results showed a tendency for increasing metabolic 
activity over the time in culture for osteoclasts, and a decrease for macrophages, particularly 
from day 14 to day 21, with a significant difference between osteoclasts and macrophages at day 
21 (Figure 3.3A).  
To further evaluate cell morphology and differentiation in Fg-3D scaffolds, osteoclasts 
and macrophages were visualized by confocal microscopy at days 7 and 21. At day 7 of culture, 
both conditions presented essentially mononuclear cells, which were dispersed in the scaffold 
(Figure 3.3B). On the other hand, cell morphologies at day 21 were different, with macrophages 
remaining essentially mononucleated cells, with occasional bi or multi-nucleated cells, while 
osteoclasts were bigger and presenting a high proportion of multinucleated cells (more than 3 
nuclei), including some cells with 10 or more nuclei (Figure 3.3B and C). Also, the osteoclastic 
marker cathepsin K was only detected for osteoclasts, and mostly only at day 21 of culture 
(Figure 3.3C).  
The capacity of both cell populations to express the TRAP enzyme was evaluated by a 
colorimetric assay at 21 days of culture. Both macrophages and osteoclasts were TRAP-positive 
at day 21 of culture (Figure 3.4, dark red/brown staining). No staining was detected in the 
scaffold without cells. 
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Figure 3.3 - Macrophages and osteoclasts differentiation on Fg-3D scaffolds. Monocytes were seeded directly on 
Fg-3D scaffolds and allowed to differentiate to macrophages or osteoclasts. (A) Metabolic activity was assessed 
through resazurin assay along time, for 4 independent experiments, using different monocyte donors. *p<0.05 
(Kruskal-Wallis, followed by Dunns). (B) Osteoclasts and macrophages were cultured for 7 and 21 days on Fg-3D, 
before cells were fixed and for cytoskeleton (green), nuclei (blue), and cathepsin K (red). (C) Higher magnification 
showing cell morphology and cathepsin K staining. Images are representative of 3 independent experiments. Scale 
bar=50 µm. (D) Fg-3D scaffolds without cells, or with macrophages or osteoclasts cultured for 21 days, were fixed 
and stained for TRAP activity (dark red/brown staining). Magnification=2x. Four donors for macrophages and 5 
donors for osteoclasts were studied. Mac-macrophages; OC – osteoclasts; TRAP – tartrate-resistant acid 
phosphatase. 
D 
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3.4. Fg-3D are degraded by macrophages and osteoclasts 
Having established that macrophages and osteoclasts could differentiate in Fg-3D 
scaffolds, and express the degradative enzymes, cathepsin K and TRAP, we proceeded to 
evaluate their capacity to degrade the scaffolds. Osteoclasts and macrophages cultured in Fg-3D 
scaffolds were observed by SEM at days 7 and 14 for macrophages and 7, 14 and 21 for 
osteoclasts. Results illustrated in Figure 3.4A show a reduction in size of the scaffold with time 
in culture. A more detailed observation revealed that scaffolds were covered by the cells. 
Confirming the confocal microscopy results, macrophages appear as individualized cells both at 
day 7 and 14, but osteoclasts appear to fuse with time in culture and by day 21 an agglomerate 
of osteoclast-like cells is visible (Figure 3.4B).  
In order to further characterize the scaffold degradation along time, Fg-3D scaffolds 
were cultured with macrophages or osteoclasts and without cells, as a control, for up to 21 days. 
Our findings showed that scaffolds without cells maintained most of their integrity, while 
scaffolds with osteoclasts or macrophages were degraded over time (Figure 3.5A). Photographs 
were taken by light microscopy and the area of the scaffold was quantified across different 
experiments (Figure 3.5B), showing that scaffolds without cells lose some of their area within 
the first week of culture and then stabilize. In presence of both osteoclasts and macrophages 
scaffold degradation was enhanced in the first week, and particularly from 7 to 14 days in 
culture. There was a significant scaffold area decrease for osteoclasts at day 14, when compared 
with scaffolds without cells at day 14. At day 21, there was a significant decrease for both 
osteoclasts and macrophages when compared with scaffolds without cells, from the same time 
point. Finally, there was a significant difference between the area at days 7 and 21, for the 
scaffolds with osteoclasts. Although macrophages also visibly degrade the Fg-3D scaffolds, area 
reduction along time was not significant. The scaffold degradation was further studied by 
quantifying the D-dimer, a specific degradation product of Fg, in culture supernatants from the 
same experiments. D-dimer quantification showed increasing levels of this small protein 
fragment being released as the scaffold is degraded (Figure 3.5C). In detail, there was a 
significant increase in D-dimer concentration along time for both macrophages and osteoclasts, 
when comparing the levels at 7 and 21 days. This is consistent with the results obtained by 
measurement of the scaffold’s area. 
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Figure 3.4 - Fg-3D scaffold degradation and cell ultrastructure. Fg-3D scaffolds were seeded with monocytes, 
that were allowed to differentiate into macrophages or osteoclasts, for 7, 14 or 21 days, as indicated. Samples were 
then observed using SEM. (A) General view of scaffolds seeded with macrophages/osteoclasts along culture time. 
Scale bar=200 µm. (B) Details of the cells ultrastructure along time in culture.  Scale bar=50 µm. Mac-macrophages; 
OC – osteoclasts. 
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Figure 3.5 - Fg-3D scaffolds are degraded by macrophages and osteoclasts. Scaffolds were left without cells, or 
seeded with monocytes that were allowed to differentiate to osteoclasts or macrophages (A) scaffold degradation was 
evaluated by light microscopy at days 7, 14 and 21 of culture. Five independent experiments with different donors 
and 2 scaffolds per experiment for each condition were analyzed. Stereomicroscope mode=Dark Field. 
Magnification=2x. (B) Scaffold area was calculated from the images collected in A, using image analysis software. 5 
to 16 samples were studied. (C) D-dimer present in culture supernatants was quantified by ELISA. Samples from 
five independent donors were used. Results are showed as cumulative concentration. *p<0.05, **p<0.01 (Kruskal-
Wallis, followed by Dunns). Mac-macrophages; OC – osteoclasts. 
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3.5. Conditioned media from macrophages and osteoclasts differentiated in Fg-3D 
is capable of inducing osteoblastic differentiation 
Coupling between osteoclasts and osteoblasts is essential to promote bone regeneration. 
So, we then investigated if macrophages and osteoclasts cultured in Fg-3D scaffolds could 
produce osteogenic factors that contributed to MSC osteoblastic differentiation. To evaluate this 
hypothesis, MSC were cultured in Fg-3D in the presence of media collected from the cultures of 
osteoclasts and macrophages in Fg-3D. Results are illustrated in Figure 3.6A, and show that 
MSC cultured in basal media, or in media supplemented with osteoclast-differentiating 
cytokines (RANKL and M-CSF) did not present ALP activity. On the other hand, MSC in basal 
conditions, supplemented with the conditioned media from osteoclasts or macrophages 
presented high levels of ALP activity, in some conditions comparable to the positive control 
media supplemented with the classical osteogenic inductors. Interestingly, for both osteoclasts 
and macrophages, the media from the first week of culture was the most potent to promote 
osteogenic differentiation, with the intensity and spreading of the ALP staining decreasing over 
the weeks. To quantify the obtained results, the percentage of ALP staining area per well was 
measured using an image analysis software. Our findings showed that conditioned media from 
the first week of differentiation, for both cell populations, had a significant increase of ALP 
activity when compared to the negative control (Figure 3.6B). Confirming what could be 
observed in the images, conditioned media from both cell populations had a decreasing effect 
over the time, with conditioned media from the third week showing the smallest percentage of 
area of red staining.  
Due to the key role of TGF-β1 in bone remodeling, its concentration in the conditioned 
media from macrophages and osteoclasts of the first and third weeks of culture was quantified. 
For both cell populations the levels of TGF-β1 were significantly higher in the first week (7 
days) when compared to the values detected in the third week (21 days) of culture (Figure 
3.6C). 
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Taken together the results presented suggest that both OC and macrophages could be 
differentiated on Fg-3D scaffolds, producing degradative enzymes and performing degradative 
and pro-regenerative functions.  
A 
B C 
Figure 3.6 - Conditioned media from osteoclasts and macrophages induce osteogenic differentiation of MSC. 
(A) MSC were cultured on Fg-3D for 14 days with basal media, or a 1:1 dilution of macrophage or osteoclast 
conditioned media. Media supplemented with chemical osteogenic inductors was used as control. Cells were then 
stained for ALP activity (red) (B) Percentage of red area was calculated using image analysis software processing on 
the images acquired in A. Four donors for osteoclasts and two donors for macrophages were studied. 
Magnification=2x. *p<0.05, **p<0.01 (Kruskal-Wallis, followed by Dunns). (C) Concentration of TGF-β1 in culture 
supernatants of macrophages and osteoclasts cultured in Fg-3D scaffolds. Six donors were studied. **p<0.01, 
***p<0.001 (ANOVA, followed by Tukey). CM – conditioned media; Mac-macrophages; OC – osteoclasts. 
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4. Discussion 
A recent study by our group [124] shows that Fg-3D scaffolds present an interconnected 
porous structure, similar to the one observed for chitosan scaffolds, previously used in our 
group [111] and fibrinogen scaffolds, produced by others, using a templating method [96]. In 
this work, we showed that after neutralization, this structure was maintained, providing a 3D 
environment for cell migration, proliferation and differentiation. The only detectable difference 
between the dry and neutralized scaffolds was the absence of NaCl crystals (as assessed by 
EDS, data not shown) in the neutralized scaffold. The NaCl in the dry scaffold likely derives 
from the PBS used to prepare the original Fg solution, with the crystals forming during 
liofilization. The removal of the crystals during the neutralization process will avoid localized 
increases in concentration of chloride and sodium ions when scaffolds were placed in culture 
media. When analyzing the behavior of scaffolds without cells, we found that after 21 days of 
incubation in culture media (α-MEM or RPMI) there were some changes to the structure, with 
less open pores and collapsed walls, though it still maintained an interconnect network. These 
alterations were more pronounced in the scaffold cultured in RPMI, maybe due to the different 
composition of the media or to slight changes in the pH.  
Previous work from our laboratory has shown that Fg-modified chitosan materials 
enhanced osteoclastogenesis in vitro [39] and bone regeneration in vivo [111]. In the current 
work, we analyzed the behavior of osteoclasts, derived from human primary monocytes on 
Fg-3D scaffolds, using macrophages as a control. The first step was to evaluate cell morphology 
in presence of extracts from Fg-3D scaffolds. As a control, we have used adsorbed Fg, in order 
to determine if effects were because of the soluble state of Fg or just its presence in cultures. Fg, 
both soluble or adsorbed, have been showed to induce osteoclast fusion [39, 121]. Also, it has 
been reported that soluble fibrinogen is correlated with a chronic inflammatory response [121, 
122]. Remarkably, adsorbed Fg does not seem to have such a disadvantage, with several reports 
showing that it may have a positive effect in osteoclastogenesis and wound healing [39, 92, 
110-112, 128] Interestingly, in our results for all conditions and time points, adsorbed Fg 
showed similar results to the control, while Fg extracts impaired cell adhesion and viability. 
Nonetheless, osteoclasts were capable of surviving until day 21 of culture in both conditions, 
and those that remained expressed cathepsin K. Of note, in both extract conditions, a white 
structure, possibly made of fibrinogen and/or fibrinogen degradation products was visible, as 
soon as day 1 of culture. Such structure was also stained and observed and contained cells 
(Annex 2). Nevertheless, cell survival was impaired, suggesting that osteoclasts may not resist 
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high concentrations of Fg degradation products. It should be noted that these are primary human 
cells and that they were in contact with extracts for prolonged periods of time, instead of the 
short term assays that are commonly used to determine cytotoxicity through quantification of 
metabolic activity [93], as recommended in ISO10993-5 standard. Here we decided to 
determine cytotoxicity by evaluating cell morphology, using longer culture times, as to allow 
cell morphology changes, similar to previous reports in the literature [129, 130]. 
On the other hand, when monocytes were cultured directly on Fg-3D scaffolds and 
allowed to differentiate to macrophages or osteoclasts, cell adhesion and multinucleated cell 
formation did not appear impaired. The decrease in metabolic activity observed for 
macrophages was most likely due to the ageing of the cells after 14 days in culture without 
addition of exogenous cytokines, and not with the effect of the scaffold. By confocal and also 
by SEM analysis cells appear to migrate into the scaffold with time in culture. However, we 
cannot rule out that some of this effect is due to the degradation of the scaffold more than to cell 
migration. In the SEM analysis osteoclast-like cells appear to fuse, forming an agglomerate by 
the end of the culture. This cell morphology is similar what has been reported in the literature 
for fibrin [131] and collagen scaffolds [132]. Interestingly, in some samples a fibrin-like 
structure [104, 105], with thin fibrils, to which the cells also adhered, could be detected (Annex 
3). The presence of this structure may be due to the formation of fibrin, perhaps helped of some 
proteins present in FBS or by the cells themselves. 
Osteoclast differentiation was investigated by examining the presence of multinucleated 
cells, and the expression of cathepsin K and TRAP enzymes. Scaffolds with osteoclasts 
presented mostly multinucleated cells, some with more than 10 nuclei. Though there were also 
occasional multinucleated cells in macrophages scaffolds, they were less and with fewer nuclei. 
The fusion of osteoclast precursors is necessary for the differentiation into fully mature 
osteoclasts to occur. Without this, osteoclasts are not capable of performing their resorbing 
activity [3]. TRAP is an enzyme involved in organic matrix degradation. It shares the same 
cellular localization of cathepsin K, vesicles, golgi complex and ruffled border of active 
osteoclasts [1, 31]. Both osteoclasts and activated macrophages [133] produce TRAP, but 
different isoforms: while osteoclasts produce TRAP-5b, macrophages produce TRAP-5a [31]. 
The assay used in this work does not differentiate between the two isoforms of TRAP and so 
both osteoclasts and macrophages have positive staining, as expected. However, TRAP is a 
marker of fully active osteoclasts, with its expression severely decreased in precursor cells. In 
order to better differentiate between osteoclasts and macrophages, direct quantification of the 
isoform 5b could be performed in the future [31]. Because the scaffold is a 3D structure where it 
is difficult to quantify the TRAP staining, released TRAP activity quantification could also be 
performed [39]. Cathepsin K is a protease produced by osteoclasts, whose function is to degrade 
collagen type I and other non-collagenous proteins during bone resorption [134]. Its presence 
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indicates resorption capable osteoclasts and helps distinguish them from macrophages, as the 
later do not express this enzyme. As such, cathepsin K is one of the biomarkers used to identify 
differentiation of monocyte/macrophage into osteoclasts [135]. Taken together, these results 
strongly indicate that human monocytes were able to successfully differentiate into 
macrophages and also mature osteoclasts in Fg-3D. 
When analyzing the cells, particularly through SEM analysis, it was possible to 
visualize the reduction of area of the scaffold in the presence of cells through time of culture 
(Fig3.5). In a previous work, we had already studied degradation of Fg scaffolds in presence of 
water and FBS, and also observed it in vivo, in a rat femur defect model [124]. Here we 
investigated this degradation in culture media without cells and mediated by osteoclasts or 
macrophages. For the scaffolds without cells, the decrease of area was mainly in the first week. 
A potential explanation could be that when cut into the appropriate cylinders, the scaffold is 
subjected to tension forces that may damage its exterior walls. These exterior walls are also the 
ones more prone to damage during the neutralization and scaffold handling before scaffold 
placement into experimental wells. Thus, overall fragility/damage, due to mechanical forces, of 
the exterior wall may explain some degradation, and thus the area decrease in the first week. It 
could be of interest to explore intermediate time points in the first week in order to establish the 
time necessary for this reduction to occur. The statistical differences between the scaffolds with 
and without cells at day 14 and 21, but not at day 7 also imply that after week 1 the cells are the 
major intervenient in scaffold degradation. This area measurement method is limited, because 
the scaffold is a 3D irregular structure and it also does not take into account the degradation that 
may be occurring inside the pores of the scaffold. However, the scaffold shape resembles a very 
thin disc with a relatively uniform height of 2 mm, allowing for an estimate area determination.  
In order to further confirm the scaffold degradation quantification, the presence of 
D-dimer in culture supernatant was quantified. D-dimer is a fibrin/fibrinogen degradation 
product formed by two crosslinking D fragments of these proteins [136]. In the clinical setting, 
it is often used as biomarker for coagulation and circulatory disorders, such as acute venous 
thrombosis, pulmonary embolism and uncontrolled coagulation [137-139]. This is because the 
presence of D-dimer is directly correlated with ongoing fibrinolysis [136]. Because of this, in 
studies with structures made of fibrin/fibrinogen or related molecules, the presence of higher 
levels of D-dimer started to be correlated with higher degradation of the 
structure/hidrogel/scaffold [102, 104, 105]. The results from the quantification of D-dimer were 
congruent with the results obtained by measurement of the scaffold’s area. In the supernatants 
of scaffold degradation through proteinase K and trypsin, it was not possible to detect the 
presence of D-dimer (data not shown), suggesting that D-dimer cannot originate by fibrinogen 
lysis by any of these molecules. It would be of interest to use an enzyme capable of degrading 
fibrinogen in D-dimer alone. One good candidate is plasmin, an enzyme present in blood, as it is 
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the main enzyme responsible for fibrinolysis of blood clots and thrombus [140]. As the quantity 
of D-dimer produced by degradation of a whole scaffold could not be measured, we cannot say 
if the amount produced in the scaffold with cells represents a small or large percentage of the 
scaffold. However, this alternative method of quantifying the D-dimer Fg degradation product 
also presented with some challenges. An analysis of the D-dimer resulting from the degradation 
of the entire scaffold was attempted, but complete enzymatic degradation using either trypsin or 
proteinase K resulted in no detectable D-dimer production (data not shown). This indicates that 
other degradation products may be formed, also by the cells, that cannot be quantified, as so 
could mask the real degradation rate.  
Despite the measurement limitations, the results presented clearly demonstrate the 
capacity of both macrophages and osteoclasts to degrade Fg-3D scaffolds, and indicate that 
osteoclasts may be more efficient in performing such degradation. As both cell populations are 
able to degrade the scaffolds, this suggests a common mechanism. As macrophages and 
osteoclasts used in this study derive from monocytes, it is possible that one of the mechanisms 
used by monocytes to degrade fibrin thrombus is also being used to degrade Fg-3D, such as the 
alternative fibrinolytic pathway, in which the integrin Mac-1 is involved, directly binding and 
internalizing fibrin/fibrinogen, resulting in its lysosomal degradation. This pathway was show to 
significantly contribute to total fibrinolysis [141]. 
Finally, we evaluated the potential functional consequences in terms of the coupling 
between osteoclasts and osteoblasts, which is essential to promote bone regeneration. So, we 
investigated if osteoclasts, and also macrophages, cultured in Fg-3D scaffolds could produce 
osteogenic factors that contributed to MSC osteoblastic differentiation. To evaluate this, MSC 
were cultured for 14 days, the peak of ALP expression [142, 143], in presence of osteoclast and 
macrophage conditioned media. Interestingly, conditioned media from both macrophages and 
osteoclasts induced the osteogenic differentiation of MSC on Fg-3D to levels comparable to the 
positive control. Of note, the highest ALP induction was observed for conditioned media from 
the first week of osteoclasts and macrophage differentiation. This suggests that osteoclasts and 
macrophages at an early differentiation stage, or their precursor cells secret paracrine factors 
capable of enhancing MSC differentiation into osteoblasts, and that the expression of those 
factor(s) decreases with cell differentiation. Similar results were obtained in a study with 
chitosan 3D scaffolds, where conditioned from the first week of culture of osteoclasts increased 
MSC osteogenic differentiation to levels identical to the ones obtained with osteogenic 
cytokines, in both chitosan-only and chitosan with adsorbed Fg scaffolds (our unpublished 
observations). The fact that conditioned media from osteoclasts promotes osteoblastogenesis is 
in agreement with the results found in the literature [144]. However, most studies regarding the 
effect of osteoclast conditioned media in MSC/osteoblasts were performed in a 2D environment, 
with no biomaterials involved. In a recent study with a murine model, conditioned media from 
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mature osteoclasts induced osteoblastogenesis and complement component 3a was identified as 
the paracrine factor responsible at an early stage [70]. Identifying the factor(s) responsible for 
these results in a human model, would allow their use as therapeutic molecules for bone 
remodeling disorders. 
In an attempt to characterize potential factors involved in promoting MSC 
differentiation, TGF-β produced by macrophages and osteoclasts along time in culture was 
quantified. TGF-β is produced by many cells, and can promote proliferation, differentiation and 
production of other cytokines. Almost all cells have receptors for TGF-β in their membrane and 
can be influence by its presence/absence. TGF-β1, TGF-β2, and TGF-β3 function through the 
same receptor signaling systems. TGF-β1 is secreted by most immune cells and has several 
roles in the maintenance of the immune system homeostasis, as, for example, the induction of 
cytokine (IL-1α, IL-1β, and TNF-α) production by monocytes/macrophages [145]. In the bone 
context, TGF-β is a cytokine capable of recruiting MSC and stimulating osteoblast precursors 
proliferation, having an important role in early stages of osteoblastogenesis [5, 9]. However, 
TGF-β has been reported to inhibit later differentiation and mineral deposition by mature 
osteoblasts [5]. Our results showed a decrease over time of the TGF-β1 concentration in the 
conditioned media. This timely regulation could constitute an advantage, as TGF-β1 is reported 
to play an positive role in early osteoblastogenesis, contributing to bone regeneration, but 
continuous high levels of this cytokine inhibits osteoblast capacity to form mineralized matrix 
[146]. Further analysis of conditioned media constituents would be important to reveal the 
presence of other factors responsible for induction of osteoblastogenesis. 
Moreover, a study using conditioned media of human osteoclasts indicates that these 
cells are capable of secreting non-bone related factors, capable of affecting positively the bone 
nodule formation by osteoblasts [62]. In another study, conditioned media from mature 
osteoclasts induced bone formation and interestingly, non-resorbing osteoclasts also seemed to 
enhance formation of mineralized matrix by osteoblasts. Contrary to our results, mature 
macrophages and osteoclasts precursors were not capable of having a positive effect on 
mineralized matrix formation [144]. This may suggest that while both osteoclasts and 
macrophages/monocytes are capable of initiate osteoblast differentiation, only osteoclasts 
enhance the bone forming capacity of osteoblasts. In order to assess this hypothesis, we would 
need to evaluate the influence of conditioned media from macrophages and osteoclasts on MSC 
capacity to produce mineralized matrix, using for example von Kossa or alizarin staining, at a 
later stage of differentiation (28 days). 
Despite the need for further experiments, these findings are promising, as a good 
coupling between osteoclasts and osteoblasts is essential for sustained bone regeneration.  
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5. Conclusions and future work 
In this work we started by testing the effect of Fg-3D extracts on cell survival and 
differentiation, using adsorbed Fg as a control. Osteoclast and macrophage survival was 
decreased in presence of Fg-3D extracts, while adsorbed Fg permitted the formation of mature 
osteoclasts (large multinucleated cells positive for cathepsin K), similar to the negative control 
(without Fg). However, when osteoclasts and macrophages were cultured in direct contact with 
Fg-3D scaffolds their survival was no longer compromised. In fact, mononuclear macrophages 
that expressed TRAP were differentiated when no cytokines were present, while RANKL and 
M-CSF led to large multinucleated osteoclasts, positive for both TRAP and cathepsin K, being 
obtained. Moreover, both osteoclasts and macrophages successfully degraded Fg-3D scaffolds, 
and produced mediators such as TGF-β1 that likely induced ALP production by MSC.  
Although the results obtained were promising further studies would be necessary to 
establish if the differentiation of osteoclasts in Fg-3D, by comparison with other biomaterials, 
could further promote the production of pro-osteogenic mediators. Because ALP is a marker for 
early osteogenic differentiation, late osteogenic differentiation markers should also be studied, 
either by gene expression analysis or using cytochemical methods that allow the detection of 
mineral deposits, such as von Kossa or alizarin stainings. Furthermore, analysis of conditioned 
media constituents could uncover other factors besides TGF-β1, that may contribute for the 
osteogenic differentiation of MSC and if such factors vary over time. Also, TGF-β1 inhibition 
studies could clarify its role in the enhanced osteogenic differentiation of MSC that was 
observed here.  
Taken together, our results suggest that Fg-3D scaffolds have potential to be used as 
biomaterial for bone regeneration, which perhaps could be enhanced by the incorporation of 
molecules that osteoclasts normally secrete, promoting the osteoblast-osteoclast coupling 
mechanisms.  
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7. Annexes 
Annex 1 
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Annex 1 - Cathepsin K staining is specific. Monocytes were seeded directly on Fg-3D scaffolds and allowed to 
differentiate to macrophages or OC. OC  were cultured for 7 on Fg-3D, before cells were fixed and stained with 
Alexa488-conjugated phaloidin (green), for cytoskeleton, DAPI (blue) for nuclei, and (A) secondary antibody alone 
(control) or (B) a primary antibody against Cathepsin K, followed by Alexa647-conjugated secondary antibody (red). 
Images are representative of 3 independent experiments. Scale bar=50 µm. E-extract; OC-osteoclasts. 
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Annex 2 
  25% E 50% E 
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OC 21d 
Annex 2 - Cells adhered to Fg extract “structure”. Osteoclasts and macrophages were cultured on uncoated 
coverslips with Fg extracts diluted in complete medium (50% E).Cell cytoskeleton was stained with Alexa488-
conjugated phaloidin (green) and nuclei with DAPI. Cell were stained with Alexa647-conjugated secondary antibody 
combined with the primary antibody against Cathepsin K. Images are representative of 3 independent experiments. 
No cells were found in one donor. Scale bar=50 µm. E-extract; Mac-macrophages; OC-osteoclasts. 
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Annex 3 
 
 
 
Annex 3 – Cells adhere to fibrin-like structure. Monocytes were seeded directly on Fg-3D scaffolds and allowed 
to differentiate to macrophages or osteoclasts. First image scale bar=20 µm, second image scale bar=10 µm. 
 
